A review of the pathophysiological mechanisms of doxorubicin …
Jan 23, 2024 · One example is cancer therapy-related cardiac dysfunction (CTRCD) caused by doxorubicin: up to 9% of the cancer patients treated with this drug develop heart failure at a later stage.
Doxorubicin-induced cardiotoxicity and risk factors - PMC
Although useful in the treatment of cancers, the benefit of DOX is limited due to its cardiotoxic effect that is observed in a large number of patients. In the literature, there is evidence that the presence of various factors may increase the risk of developing DOX-induced cardiotoxicity.
Subclinical doxorubicin-induced cardiotoxicity update: role of ...
The roles of systemic inflammation, endothelial injury and neutrophil recruitment, all induced by the DOX, are increasingly recognized as the mechanisms that trigger the development and progression of DOX-induced cardiomyopathy.
Doxorubicin Cardiomyopathy - PMC - National Center for …
Dec 11, 2009 · Doxorubicin cardiotoxicity can be acute, occurring during and within 2–3 days of its administration. The incidence of acute cardiotoxicity is approximately 11% [3,4]. The manifestations are usually chest pain due to myopericarditis and/or palpitations due to sinus tachycardia, paroxysmal nonsustained supraventricular tachycardia and premature ...
Regulated cell death pathways in doxorubicin-induced ... - Nature
Apr 1, 2021 · This review focuses on recent advances in our understanding of doxorubicin induced regulated cardiomyocyte death pathways including autophagy, ferroptosis, necroptosis, pyroptosis and apoptosis.
Doxorubicin Exposure Causes Subacute Cardiac Atrophy …
Mar 15, 2019 · Doxorubicin causes a subacute decrease in cardiac mass in both mice and humans. In mice, doxorubicin-induced cardiac atrophy is dependent on MuRF1. These findings suggest that therapies directed at preventing or reversing cardiac atrophy might preserve the cardiac function of cancer patients receiving anthracyclines. WHAT IS NEW? •.
Nrf2: a dark horse in doxorubicin-induced cardiotoxicity
Jul 26, 2023 · In this review, we intend to emphasize the pivotal role of Nrf2 in doxorubicin-induced cardiotoxicity, in particular, the involvement of Nrf2 as a crucial mechanism in the pathology of...
Targeting OCT3 attenuates doxorubicin-induced cardiac injury
Feb 2, 2021 · Doxorubicin is a commonly used anticancer agent that can cause debilitating and irreversible cardiac injury. The initiating mechanisms contributing to this side effect remain unknown, and current preventative strategies offer only modest protection.
Doxorubicin Cardiotoxicity: Pathophysiology Updates
Oct 14, 2020 · Introduction. Anthracyclines are chemotherapeutic agents that have been used to treat a broad range of malignancies for the past several decades. Doxorubicin is a potent anthracycline used in the treatment of breast cancer, leukemia, lymphoma, and sarcoma.
Doxorubicin-related cardiotoxicity: review of fundamental …
Nov 1, 2024 · Volume 73, November–December 2024, 107683. Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury. Author links open overlay panel. Ashot Avagimyan a. , Nana Pogosova b c. , Lev Kakturskiy d. , Mohammad Sheibani e f. , Abhiram Challa g. , Eugenia Kogan h. , Federica Fogacci i. , Liudmila Mikhaleva d. ,